Consistent with above, previous reports have highlighted that increase in levels and addiction to MCL1 and/or Bcl-xL confers innate or acquired resistance to venetoclax in leukemia and lymphoma cells (Fig. 7)29,30. The gene discussed is MCL1; the disease is lymphoma.